VIA
ALLO icon

Vident Investment Advisory’s Allogene Therapeutics ALLO Stock Holding History

Vident Investment Advisory’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-101,213
Closed -$500K – 1183
2023
Q1 		$500K Sell
101,213
-2,913
-3% -$18.7K 0.02% 780
2022
Q4 		$655K Buy
104,126
+38,995
+60% +$361K 0.02% 622
2022
Q3 		$702K Sell
65,131
-6,885
-10% -$93.6K 0.02% 686
2022
Q2 		$821K Sell
72,016
-5,441
-7% -$48.3K 0.02% 691
2022
Q1 		$706K Buy
77,457
+12,910
+20% +$134K 0.02% 817
2021
Q4 		$963K Buy
64,547
+7,968
+14% +$141K 0.03% 720
2021
Q3 		$1.45M Sell
56,579
-4,042
-7% -$96K 0.04% 556
2021
Q2 		$1.58M Buy
60,621
+1,057
+2% +$30.1K 0.05% 499
2021
Q1 		$2.1M Hold
59,564
– – 0.07% 354
2020
Q4 		$1.5M Buy
59,564
+29,228
+96% +$953K 0.06% 403
2020
Q3 		$1.14M Sell
30,336
-6,070
-17% -$229K 0.06% 452
2020
Q2 		$1.56M Sell
36,406
-18,342
-34% -$663K 0.08% 296
2020
Q1 		$1.06M Sell
54,748
-1,322
-2% -$31.5K 0.07% 373
2019
Q4 		$1.46M Buy
56,070
+3,247
+6% +$89.4K 0.09% 338
2019
Q3 		$1.44M Sell
52,823
-1,509
-3% -$43K 0.13% 119
2019
Q2 		$1.46M Sell
54,332
-4,998
-8% -$139K 0.12% 122
2019
Q1 		$1.72M Sell
59,330
-1,352
-2% -$39.2K 0.09% 314
2018
Q4 		$1.63M Buy
+60,682
New +$1.61M 0.09% 300

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vident Investment Advisory's ALLO Position: Q2 2023 in Review

Vident Investment Advisory sold out of Allogene Therapeutics (ALLO) in Q2 2023, closing a stake of 101,213 shares — an estimated $500K sold.

Vident Investment Advisory first reported a position in ALLO in Q4 2018 and held it in 18 quarters. The position peaked at $2.1M in Q1 2021. 171 funds tracked by Wall St. Rank hold ALLO as of Q2 2023.

  • Vident Investment Advisory reported no remaining Allogene Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 101,213 Allogene Therapeutics shares in Q2 2023, an estimated $500K.
  • Vident Investment Advisory first reported a position in Allogene Therapeutics in Q4 2018 and held it in 18 quarters.
  • Vident Investment Advisory's Allogene Therapeutics position peaked at $2.1M in Q1 2021.
  • 171 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2023.

Based on Vident Investment Advisory's 13F filing for Q2 2023, filed 11 Aug 2023.